Bacillus clausii is a rod-shaped, Gram-positive, motile and spore-forming bacterium that lives in the soil. It is classified as probiotic microorganism that maintains a symbiotic relationship with the host organism. B. clausii spores are able to survive in the gastric environment and reach the intestine where they can germinate to vegetative forms. This characteristic is crucial for a microorganism used in oral bacteriotherapy. Bacillus clausii SNZ 1971 is a GRAS approved ingredient.
B. clausii as a ‘spore probiotic’ has several unique properties such as the resistance to commonly used antibiotics, the absence in normal resident intestinal flora and the sporogenic activity. It can induce immune-modulatory effects and maybe change microbiota composition by contact or through bacteriocins production. Clinically, it is safe and well tolerated in adults and children on the base of more than 40 years of clinical usage.
The use of B. clausii spores in the treatment or prevention of gut barrier impairment has been largely investigated in the last years. B. clausii strains release antimicrobial substances in the medium. These substances were active against Gram-positive bacteria, in particular against Staphylococcus aureus, Enterococcus faecium, and Clostridium difficile. It is currently being studied in respiratory infections and some gastrointestinal disorders. B. clausii appears to regulate anti- and pro-inflammatory cytokine production. It is recommended for AAD and as coadjuvant for H. pylori eradication therapy. It can also be a therapeutical option in prevention and treatment of infectious diarrhea and in treatment of SIBO.
Proven Stability in a
variety of dosage forms